Faisal Mehmud

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2014 · 439 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

Thierry André, Jose M. Reyes-Vidal, Lætitia Fartoux et al. · British Journal of Cancer · 2008 · 174 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2012 · 67 citations

Medicine, Oncology, Pharmacotherapy +13

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries

Camillo Porta, Antonin Lévy, Robert D. Hawkins et al. · Cancer Medicine · 2014 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

William Oh, David F. McDermott, Camillo Porta et al. · International Journal of Oncology · 2013 · 36 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15